CP-4055

DRUG4 trials

Sponsors

Clavis Pharma

Conditions

AMLAdvanced Colorectal CancerColorectal CancerHematologic MalignanciesMalignant MelanomaOvarian Cancer

Phase 1

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

CompletedNCT00405743

Clavis PharmaAML, Hematologic Malignancies

Start: 2006-05-31End: 2010-05-31Updated: 2013-09-18

A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer

CompletedNCT00831636

Clavis PharmaOvarian Cancer

Start: 2008-04-30End: 2010-04-30Updated: 2013-09-13

Phase 2

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

CompletedNCT00498836

Clavis PharmaMalignant Melanoma

Start: 2007-03-31End: 2008-10-31Updated: 2013-09-12

A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

CompletedNCT00498407

Clavis PharmaAdvanced Colorectal Cancer, Colorectal Cancer

Start: 2007-05-31End: 2008-12-31Updated: 2009-06-04